100
Participants
Start Date
February 18, 2025
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
Domvanalimab
Administered intravenously
Zimberelimab
Administered intravenously
Paclitaxel
Administered intravenously
Carboplatin
Administered intravenously
RECRUITING
Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
RECRUITING
Westmead Hospital, Sydney
RECRUITING
Alfred Health, Melbourne
RECRUITING
Monash Health, Clayton
RECRUITING
ICON Cancer Center, Kurralta Park
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
RECRUITING
Chang Gung Memorial Hospital, Linkou, Taoyuan District
RECRUITING
CHU de Bordeaux, Pessac
RECRUITING
Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research, Nashville
RECRUITING
China Medical University Hospital, Taichung
RECRUITING
Hospital Universitario Virgen del Rocio, Seville
RECRUITING
Siteman Cancer Center, St Louis
RECRUITING
The University of Texas, MD Anderson Cancer Center, Houston
RECRUITING
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
RECRUITING
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
RECRUITING
Sarawak General Hospital, Sarawak
RECRUITING
National Taiwan University Hospital, Taipei
RECRUITING
Shanghai East Hospital, Shanghai
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
RECRUITING
Sichuan Cancer Hospital, Chengdu
RECRUITING
Barts Health NHS Foundation Trust, London
RECRUITING
The Royal Marsden NHS Foundation Trust, London
Lead Sponsor
Collaborators (1)
Arcus Biosciences, Inc.
INDUSTRY
Gilead Sciences
INDUSTRY